These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 3521192)

  • 1. Calcium channel blockers and pulmonary hypertension.
    Andersson KE
    Acta Pharmacol Toxicol (Copenh); 1986; 58 Suppl 2():113-8. PubMed ID: 3521192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calcium channel blockers in hypoxic pulmonary hypertension.
    Kennedy TP; Michael JR; Summer W
    Am J Med; 1985 Feb; 78(2B):18-26. PubMed ID: 3976691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of adenosine in combination with calcium channel blockers in patients with primary pulmonary hypertension.
    Inbar S; Schrader BJ; Kaufmann E; Vestal RE; Rich S
    J Am Coll Cardiol; 1993 Feb; 21(2):413-8. PubMed ID: 8426006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calcium blockage in pulmonary hypertension and hypoxic vasoconstriction.
    Neely CF; Stein R; Matot I; Batra V; Cheung A
    New Horiz; 1996 Feb; 4(1):99-106. PubMed ID: 8689279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic application of calcium-channel antagonists for pulmonary hypertension.
    Packer M
    Am J Cardiol; 1985 Jan; 55(3):196B-201B. PubMed ID: 3881914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nifedipine inhibits pulmonary hypertension but does not prevent decreased lung eNOS in hypoxic newborn pigs.
    Fike CD; Kaplowitz MR
    Am J Physiol; 1999 Sep; 277(3):L449-56. PubMed ID: 10484451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vasodilatory treatment of pulmonary hypertension.
    Widimský J
    Eur J Respir Dis; 1986 Mar; 68(3):161-6. PubMed ID: 2870937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effects of nifedipine, verapamil, and diltiazem on experimental pulmonary hypertension.
    Young TE; Lundquist LJ; Chesler E; Weir EK
    Am J Cardiol; 1983 Jan; 51(1):195-200. PubMed ID: 6571766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse hemodynamic and clinical effects of calcium channel blockade in pulmonary hypertension secondary to obliterative pulmonary vascular disease.
    Packer M; Medina N; Yushak M
    J Am Coll Cardiol; 1984 Nov; 4(5):890-901. PubMed ID: 6491082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pulmonary circulation and Ca-antagonists].
    Maruyama Y; Maehara K; Morita M
    Nihon Rinsho; 1989 Aug; 47(8):1776-80. PubMed ID: 2585740
    [No Abstract]   [Full Text] [Related]  

  • 11. Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension.
    Sitbon O; Humbert M; Jagot JL; Taravella O; Fartoukh M; Parent F; Herve P; Simonneau G
    Eur Respir J; 1998 Aug; 12(2):265-70. PubMed ID: 9727772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of carbon dioxide inhalation on pulmonary hypertension induced by increased blood flow and hypoxia.
    Chuang IC; Yang RC; Chou SH; Huang LR; Tsai TN; Dong HP; Huang MS
    Kaohsiung J Med Sci; 2011 Aug; 27(8):336-43. PubMed ID: 21802645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Porcine pulmonary artery and bronchial responses to endothelin-1 and norepinephrine on recovery from hypoxic pulmonary hypertension.
    Schindler MB; Hislop AA; Haworth SG
    Pediatr Res; 2006 Jul; 60(1):71-6. PubMed ID: 16690956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of inhalation of nitroglycerin on hypoxic pulmonary vasoconstriction.
    Bando M; Ishii Y; Kitamura S; Ohno S
    Respiration; 1998; 65(1):63-70. PubMed ID: 9523370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy.
    Rich S; Brundage BH
    Circulation; 1987 Jul; 76(1):135-41. PubMed ID: 2954725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo gene transfer of the O2-sensitive potassium channel Kv1.5 reduces pulmonary hypertension and restores hypoxic pulmonary vasoconstriction in chronically hypoxic rats.
    Pozeg ZI; Michelakis ED; McMurtry MS; Thébaud B; Wu XC; Dyck JR; Hashimoto K; Wang S; Moudgil R; Harry G; Sultanian R; Koshal A; Archer SL
    Circulation; 2003 Apr; 107(15):2037-44. PubMed ID: 12695303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment with the Kv7 potassium channel activator flupirtine is beneficial in two independent mouse models of pulmonary hypertension.
    Morecroft I; Murray A; Nilsen M; Gurney AM; MacLean MR
    Br J Pharmacol; 2009 Aug; 157(7):1241-9. PubMed ID: 19508393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of hypoxic pulmonary vasoconstriction by nifedipine.
    Kennedy T; Summer W
    Am J Cardiol; 1982 Oct; 50(4):864-8. PubMed ID: 7124646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Halothane differentially decreases 5-hydroxytryptamine-induced contractions in normal and chronic hypoxic rat pulmonary arteries.
    De Crescenzo V; Dubuis E; Constantin S; Rebocho M; Girardin C; Bonnet P; Vandier C
    Acta Physiol Scand; 2001 Nov; 173(3):247-55. PubMed ID: 11736687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pulmonary Vasodilators and Anesthesia Considerations.
    Green JB; Hart B; Cornett EM; Kaye AD; Salehi A; Fox CJ
    Anesthesiol Clin; 2017 Jun; 35(2):221-232. PubMed ID: 28526144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.